Efficacy and safety of TPO-RA combined with sirolimus in the treatment of relapsed immune thrombocytopenia - PubMed
3 hours ago
- #sirolimus
- #TPO-RA
- #immune thrombocytopenia
- Study evaluates TPO-RA combined with sirolimus for relapsed immune thrombocytopenia (ITP).
- Retrospective analysis of 50 patients showed ORR of 61%, 76%, and 82% at 4, 8, and 12 weeks.
- Median time to response was 7 days, with significant platelet count improvements.
- No significant efficacy difference between hetrombopag and eltrombopag subgroups.
- Patients with ITP for less than one year benefited more (p = 0.003).
- Combination therapy demonstrated manageable safety and high response rates.